C16orf92

Across TCGA pan-cancer cohorts, C16orf92 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C16orf92 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher C16orf92 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C16orf92 expression acts as an unfavorable survival marker.

READ, SARC, and LGG are the cancer types where C16orf92 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	II,III,IV	0.111	0.800	.001	9	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C16orf92–READ (DFS)

Open the READ breakdown →